 World News
 World Bio Tech (14)
 USA (202)
 Bay Area
Bay Area Bio Tech (91)
 Genentech (44)
 Business
 Bio Tech
2007 (4)
2006 (9)
2005 (6)
2004 (4)
2003 (4)
2002 (1)
 Bio Tech on Wikipedia
 Bio Tech on Web
 Bio Tech Books
 Real Estate
|
|
|
| Aug.17 |
|
Recruiters eye Genentech employees| While Roche mulls whether to raise its offer price for biotechnology powerhouse, many prized Genentech professionals | |
|
|
| Apr.30 |
|
Bad news on cancer drug Rituxan| Shares in Genentech sagged, after the company said Rituxan failed to curb symptoms of the debilitating autoimmune disorder | |
|
|
| Feb.22 |
|
FDA Clears Avastin for Breast Cancer| A Genentech drug received federal approval, a surprise decision | |
|
|
| Dec.5 |
|
FDA Panel Rejects Avastin, stock drops| Shares dropped nearly 9% after a panel of medical experts said FDA should deny approval of the company's blockbuster drug | |
|
| Aug.3 |
|
Genentech completes Tanox acquisition Genentech Inc. that it has completed the $919 million acquisition of its partner in the development of the asthma drug Xolair
|
| |
|
| Mar.24 |
|
Genentech projects quarter to be 'flat' Genentech expects U.S. sales in the first 3 months of the year to be essentially flat compared with the previous quarter
|
|
| Dec.21 |
|
Genentech gets rights to drug Genentech is agreeing to pay $280 million for rights to a growth hormone product developed by a Massachusetts company
|
| Sep.12 |
|
Avastin approval slowed by FDA Feds requested further data on the use of the drug for advanced breast cancer
|
| Aug.12 |
|
Cancer drug review extended FDA has extended by up to 90 days its review of Herceptin for treatment of patients with breast cancer.
|
| Jul.31 |
|
Tony Blair Visits Genentech Headquarters Heavy hitters from biotech firms sat down for an extraordinary talk with British Prime Minister
|
| Jul.11 |
|
2Q Profit Soars to $531 Million The biotechnology company blew past Wall Street expectations with a 79% surge in second quarter earnings
|
| Jul.1 |
|
FDA approves blindness drug Genentech Inc. won approval to market Lucentis, to restore sight in patients afflicted with a common eye disease
|
| Jun.29 |
|
2 drugs set to fight blindness
|
| Feb.13 |
|
Cancer Drug Trials Scaled Back Avastin only targets cancer, and leaves healthy cells alone
|
| Jan.10 |
|
Genentech Best Company to Work in U.S.
|
|
| |
|
| Oct.10 |
|
Big 3rd Quarter Gains
|
| Jul.11 |
|
Profits Soar 73% in 2Q The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents
|
| |
|
| Apr.16 |
|
Avastin helps those with breast cancer Genentech Inc.'s pioneering colon cancer is already showing potential as a lung cancer treatment
|
| Jan.10 |
|
4th best place to work for in U.S. Biotechnology rated fourth by Fortune
|
|
| Nov.29 |
|
Avastin helps sickest patients Genentech's novel colon cancer-fighting drug helped some of the patients stay alive 2 months longer than expected
|
| Oct.6 |
|
Profits surge on drug sales Genentech reported a 52% surge in 3rd-quarter net income, fueled by strong drug sales across its product line
|
| |
|
| Feb.26 |
|
FDA approves cancer fighter Avastin Genentech began shipping its widely anticipated colon cancer-fighting drug just hours after the government approval
|
|
| Aug.15 |
|
Firm: Genentech refuses to share profits Fremont: Shares of Protein Design lost 25% after. Company is fighting over the rights to a recently approved asthma drug
|
| May.19 |
|
Encouraging results with cancer drug| Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45% | |
|
| May.12 |
|
Arthritis drug fails key experiment The biologically engineered Raptiva failed to effectively treat patients in a key experiment
|
| |
|
|
| Sep.10 |
|
Stock plummets 9.7% Avastin, once-promising experimental breast cancer drug, had failed a clinical trial
Neighbor  Real Estate:
Add a favorite (file a bookmark) to Genentech, Bio Tech Timeline
Please send feedback to: support@mapreport.com
Advertise on Genentech, Bio Tech Page
|
